Med students say they're gift-resisitant, but peers aren't

Aaron Kesselheim
Aaron Kesselheim

A study published in the Journal of General Internal Medicine found that many medical students and residents felt confident that they could accept gifts from the pharmaceutical industry and remain unbiased—although they weren't so sure about their peers.

Those responses are one more example of what is by now a familiar split. A late 2012 ethics study showed doctors fell on both sides of the conflict-of-interest issue, with some saying a free meal from a medical supplier would not influence their prescribing choices, and others saying  the more distance between doctors and industry, the better.

The JGIM study, which was conducted by a team under the direction of Harvard Medical School assistant professor Aaron Kesselheim, focused on 1,610 students. It found that despite school gift bans, the number of medical students receiving industry gifts was up, with 33% of first-year medical students saying they had been given gifts and 56.8% of fourth-year students saying they'd been similarly treated. Gifts included items like off-site meals and samples.

This could appear at odds with an earlier BMJ study, which showed schools with gift bans seemed to have pitch-resistant docs, but Kesselheim told MM&M that these studies, while  part of the same narrative of medical-industry contact, do not overlap. He added that the lack of differentiation in industry contact among ban-free and gift-ban schools could be because school policies were not enforced at hospitals or practices.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.